FabiFlu Favipiravir 200 mg Tablets

उत्पाद विवरण

1. Technical Specifications

2. Product Description

FabiFlu 200 mg Tablet contains Favipiravir, an antiviral drug initially developed for influenza. It works by inhibiting the RNA-dependent RNA polymerase (RdRp) enzyme, thereby preventing viral replication inside human cells.

During the COVID-19 pandemic, it was approved under emergency/clinical use authorization in India for the treatment of mild to moderate COVID-19 infections. It may also be investigated for other viral infections.

3. Product Highlights

4. Therapeutic Uses

• Treatment of mild to moderate COVID-19 infection (in specific patients as per guidelines)

• Investigated for influenza and other viral infections

5. Side Effects

Common:

• Diarrhea

• Nausea, vomiting

• Elevated uric acid levels (hyperuricemia)

• Increased liver enzymes (ALT, AST)

Serious (rare):

• Liver toxicity

• Severe allergic reactions (rash, swelling, breathing difficulty)

• Decreased neutrophil count (neutropenia)

• Teratogenicity (harmful for fetus if taken during pregnancy)

6. Precautions

• Should be used only under medical supervision

• Not recommended in pregnant or breastfeeding women (can cause fetal harm)

• Men and women should use effective contraception during treatment and after completion (due to teratogenic risk)

• Dose adjustment may be required in renal and hepatic impairment

• Avoid alcohol during therapy (can worsen liver side effects)

• Monitor liver function, uric acid levels, and blood counts during treatment